Navigation Links
PROLOR Biotech's Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
Date:9/27/2010

ow News, Clinical Trials & Medical Discoveries Click to view news release full screen  

PROLOR Biotech's Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society

 

NES-ZIONA, Israel, Sept. 27 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that data from its longer-acting human growth hormone (hGH-CTP) program will be featured in an oral scientific presentation at the 5th International Congress Of The Growth Hormone Research Society (GRS) and IGF Society on October 4, 2010.

PROLOR is developing hGH-CTP to provide growth hormone-deficient adults and children with therapy that requires only once-weekly or bi-monthly injections, rather than the multiple injections per week required by current growth hormone regimens.  hGH-CTP is currently in a Phase II clinical trial following a successful Phase I trial that showed that hGH-CTP met all safety and tolerability endpoints and could potentially be effective when injected just twice per month.  

The hGH-CTP Phase II trial is a randomized, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic properties of hGH-CTP injected either weekly or twice-monthly in patients with growth hormone deficiency who currently receive daily injections of growth hormone.  The trial is being conducted at up to 14 sites in six countries.  PROLOR expects to complete
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
2. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
3. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
4. PROLOR Biotech to Present at the UBS 2009 Global Life Sciences Conference
5. PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone
6. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
7. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
8. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
9. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
10. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
11. UC Riverside researcher develops novel method to grow human embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... to progressing its ground-breaking technology platforms to Phase 1 ... the Company delivers the best value for shareholders. ... said the Company currently had an extensive program of ... and academic partnerships and initiatives, and he was working ...
(Date:7/29/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today announced ... Officer has resigned.  The Company has hired Andrew ... in December 2014, as full time interim CFO and ... Andy Ashworth began his employment today, ... transition.  Andy was the Company,s CFO from September 2011 ...
(Date:7/29/2015)... 29, 2015  AsureQuality and Ubiquitome have agreed ... applications in food and primary production sectors. The ... PCR device, the Freedom4. AsureQuality provides ... the supermarket shelf for producers, processors and Competent ... animal disease control and pest management and surveillance ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... April 4, 2012 Lixte Biotechnology Holdings, Inc. announced ... States Patent and Trademark Office for its lead histone ... Dr. John Kovach, founder and president of Lixte, ... of skin lymphomas and many other HDACi in various ...
... brain tumors with a combination of chemotherapy and radiation ... than two years after diagnosis. The effectiveness of the ... healthy brain tissue, which restricts chemotherapy access to the ... To address this challenge, researchers from the Georgia ...
... professor in the Department of Mechanical, Aerospace, and Nuclear ... Faculty Early Career Development Award (CAREER) from the National ... $500,000 award to further his research into the design ... CAREER Award is given to faculty members at the ...
Cached Biology Technology:Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 2Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 3Novel compound halts tumor spread, improves brain cancer treatment in animal studies 2Novel compound halts tumor spread, improves brain cancer treatment in animal studies 3Novel compound halts tumor spread, improves brain cancer treatment in animal studies 4Rensselaer professor Jie Lian receives NSF CAREER Award 2
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... Hurricanes are the costliest natural disasters that strike ... withstand -- or fail to withstand a hurricane ... to protect human lives and enhance resiliency. ... the U.S. Department of Commerce today announced that the ...
... a millimeter in size. Exhibiting novel and often surprising properties, ... equally innovative products. In medical therapies, for example, tiny nanovehicles ... So far, the only way of testing these approaches has ... the activation of a transported gene inside a cell for ...
... is not the best way to monitor fish populations, if ... The fish population in coral reef areas is often assessed ... these methods may misrepresent the number of fish. A ... the divers and snorkelers who try to count them. Not ...
Cached Biology News:University of Miami receives stimulus funds for study of hurricane impacts on structures, ecosystems 2University of Miami receives stimulus funds for study of hurricane impacts on structures, ecosystems 3Chasing tiny vehicles 2Chasing tiny vehicles 3
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
... 8G8/5 GenBank Accession Number : NM_002542 ... fusion protein corresponding to residues 166-223 of ... AP-2γ Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M ... of glycerol to 30% Quality Assurance: routinely ...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... a lesser extent in breast, lung and ... shows no cross-reaction with MUC1 and MUC2. ... human MUC3 Immunogen: MUC3 tandem ...
Biology Products: